Transdermal Delivery of Botulinum Toxin for the Management of Oily and Acne-Prone Skin Using TDA Technology

Intradermal botulinum toxin injections have been shown to reduce sebaceous gland activity and improve skin texture in patients with oily and acne-prone skin. However, needle-based application is associated with discomfort and potential side effects.

To evaluate the clinical efficacy and safety of transdermal delivery of botulinum toxin (150 kDa) using Transdermal Application (TDA) technology for the treatment of oily and acne-prone skin.

In this single-center observational study, 19 participants (aged 20-50) underwent treatment with the DERMADROP MED TDA device according to the BIOBOTOX protocol. Objective assessments included Sebumeter measurements and 2D/3D skin imaging. Subjective evaluation was conducted using validated patient-reported outcome measures (OSIS, OSSAS) at baseline, 2 weeks, and 4 weeks posttreatment.

A statistically significant reduction in sebum levels was observed, accompanied by notable improvements in self-reported skin clarity and satisfaction. No adverse events were reported.

Transdermal application of botulinum toxin using TDA-based DERMADROP MED technology is a safe, well-tolerated, and effective noninvasive treatment modality for reducing sebaceous activity and improving the appearance of oily and acne-prone skin.